Biogen Inc. (BIIB)
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period").
European Commission grants marketing approval to Biogen's ALS drug
Biogen said on Thursday that the European Commission has granted marketing authorization under exceptional circumstances for its amyotrophic lateral sclerosis (ALS) drug Qalsody.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
BIOGEN LEGAL DEADLINE NOTICE: BFA Law Reminds BIIB Investors About Approaching Deadline in Securities Fraud Case After Significant Stock Drops
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting Click Here
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
Biogen Buys Biotech Firm HI-Bio to Boost Its Immunology Portfolio
Biogen (BIIB) announced Wednesday it had purchased privately-held Human Immunology Biosciences (HI-Bio) for at least $1.15 billion to expand its reach into immunology medicines.
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in milestone payments
Biogen Inc. BIIB, -1.68% said Wednesday it's acquiring privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in potential milestone payments in a move aimed at bolstering its immunology portfolio. Hi-Bio's lead asset felzartamab is a fully human anti-CD38 monoclonal antibody that has shown clinical proof of concept in treating rate immune-mediated indications, Biogen said in a statement.
Biogen to buy Human Immunology Biosciences in up to $1.8 bln deal
Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for $1.15 billion in upfront and up to $650 million in potential milestone payments.
